schizophrenia, food and drug administration
FDA Approves groundbreaking drug for schizophrenia treatment
On Thursday, the U.S. Food and Drug Administration (FDA) approved the drug Cobenfy which targets schizophrenia in a new way. Cobenfy (xanomeline and trospium chloride) capsules are the first antipsychotic drug approved to target cholinergic receptors. All other treatments available for schizophrenia target the dopamine receptors.
FDA Approves the First New Schizophrenia Drug in Decades
Developed by Karuna Therapeutics, which was subsequently acquired by Bristol Myers Squibb, the drug works in an entirely different way from existing medications for schizophrenia, which is building excitement and enthusiasm among doctors and patients alike.
This FDA-approved drug promises a new way to treat schizophrenia
Bristol Myers Squibb's drug, KarXT, improved symptoms of adults with schizophrenia and had fewer side effects than antipsychotic treatments
Cobenfy: The First New Schizophrenia Drug in Decades
The FDA approved Cobenfy, a new drug for people with schizophrenia that comes with fewer side effects than other antipsychotics.
New schizophrenia drug gets FDA approval, taking novel approach to treating brain disorder
On Thursday, the U.S. Food and Drug Administration approved COBENFY, an oral medication that marks the first new class of drugs for schizophrenia in more than 30 years.
FDA approves 1st new drug for schizophrenia in more than 30 years
The U.S. Food and Drug Administration (FDA) on Thursday approved the first new drug to treat people with schizophrenia in more than 30 years.
FDA approves Cobenfy, a first-in-class schizophrenia drug
The US Food and Drug Administration has approved Cobenfy, also known as KarXT, a new schizophrenia treatment. The drug was developed by Karuna Therapeutics, which was bought by Bristol Myers Squibb (BMS) last year for $14 billion.
FDA Approves Potentially Groundbreaking Schizophrenia Drug
On Thursday, the Food and Drug Administration approved Cobenfy, a drug from Bristol Myers Squibb—the first truly novel treatment for schizophrenia in decades.
FDA approves new schizophrenia drug
The U.S. Food and Drug Administration has approved a new drug for adults with schizophrenia,  the FDA announced Thursday.
FDA approves new type of schizophrenia drug
The U.S. Food and Drug Administration (FDA) on Friday approved a new drug used for treating schizophrenia in adults, according to a press release. “This drug takes the first new approach to schizophrenia treatment in decades,
FDA Approves Cobenfy, Pioneering New Approach to Schizophrenia Treatment
The U.S. Food and Drug Administration (FDA) has approved Cobenfy (xanomeline and trospium chloride) for the treatment of schizophrenia in adults. This innovative medication marks a significant
Valley News Live15h
FDA approves new drug for schizophrenia, described as a potential ‘game changer’
FARGO, N.D. (Valley News Live) - Changes are coming to the way schizophrenia is treated. The US Food and Drug ...
The Washington Post on MSN4d
FDA approves a novel drug for schizophrenia, a potential ‘game changer’
“This drug takes the first new approach to schizophrenia treatment in decades,” Tiffany Farchione, director of FDA’s ...